In Depth: How China’s Pricing Regime Penalizes Innovative Drugmakers

For nearly a decade, China’s domestic drug pricing policy has frustrated pharmaceutical companies.

Since 2016, the national insurance regulator has haggled with companies eager to have their innovative drugs covered by state health insurance, to help lower costs for patients.

This has made profits elusive for these companies. As a result, some have expanded into foreign markets in search of wider margins.